Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott and AstraZeneca cholesterol drug combination meets primary endpoints

Abbott and AstraZeneca cholesterol drug combination meets primary endpoints

2nd June 2008

Abbott has announced the publication of phase III clinical trial results of its investigational cholesterol drug TriLipix (ABT-335) used in combination with Crestor (rosuvastatin calcium) from AstraZeneca.

The firm reported that the combination met the primary endpoints on LDL, triglycerides and HDL cholesterol, improving all three lipids while reported safety was consistent with the monotherapies.

No unexpected liver, kidney or muscle safety signals nor rhabdomyolysis were identified with either the monotherapies or combination treatment.

Data from the study involving over 1,400 patients was presented last week at the scientific sessions of the National Lipid Association.

Peter H Jones, of the Methodist DeBakey Heart and Vascular Centre in Houston, said: “Patients with mixed dyslipidemia need treatment options that address all three key lipids, including LDL, HDL and triglycerides.”

He added that the results from the phase III study showed the combination to significantly increase HDL, while lowering LDL and triglycerides, potentially offering physicians treating patients with mixed dyslipidemia an important statin/fibrate combination therapeutic option.

In March 2008, Abbott presented study results to the American College of Cardiology showing that TriLipix used in combination with atorvastatin and simvastatin improved LDL, HDL and triglycerides compared to corresponding monotherapies.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.